Form 4: Director Mark Stolper Acquires Oncology Institute Stock

Director Mark Stolper of Oncology Institute, Inc. reported the acquisition of 25,833 shares of common stock through a fully vested RSU award.

Summary

• Director Mark Stolper acquired 25,833 shares of common stock in Oncology Institute, Inc.
• The acquisition was made through a Restricted Stock Unit (RSU) award that was fully vested upon grant.
• The transaction date was July 7, 2026, and the reported acquisition amount was 25,833 shares at a price of $0.00.
• Following this transaction, Mr. Stolper beneficially owns 25,833 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports on a routine stock award to a director rather than indicating significant new investment or strategic shifts.

Positives

• Director acquisition of shares can signal confidence in the company's future prospects.
• The shares were acquired through a vested RSU award, indicating a form of compensation for services rendered.

Future Outlook

No specific forward-looking statements or guidance were provided in this filing.

Industry Context

StockSavvy.ai notes that director stock acquisitions, particularly through vested awards, are common disclosures under SEC Rule 16 and often reflect compensation structures rather than new investment decisions. The oncology sector continues to see innovation, but regulatory and reimbursement landscapes remain critical factors.

Stakeholder Impact

• Shareholders: The acquisition by a director may be viewed positively as a sign of insider commitment, though the shares were acquired via a vested award, not open market purchase.

Key Dates

Keywords

Form 4, SEC Filing, Beneficial Ownership, Stock Acquisition, Director, Oncology Institute, TOI, RSU Award